OREF Skeletal Metastases and Pathological Fracture Research Grant in Collaboration with the Musculoskeletal Tumor Society (MSTS)
$25,000
RFA Release Date - 3/7/2024 LOI Deadline - N/A Application Deadline - 6/20/2024
Grant Details
Solicits investigator-initiated research proposals focused on skeletal metastases. With advances in targeted therapies and personalized medicine, patients with advanced cancers and skeletal metastases live longer. The incidence of pathological fractures is ever increasing. There are unmet needs for new knowledge, new effective treatments, and improved outcomes concerning skeletal metastases from other organs. Major research areas under this RFA may include, but are not limited to the following topics:
- Metastatic cancer-induced bone loss
- Molecular or biomechanical mechanisms of skeletal metastases
- Pathophysiology of pathological fractures
- Management and clinical outcomes of impending and established pathological fractures secondary to cancer metastases to bone
Please note: ProposalCentral now requires applicants to log in to view grant opportunities. To view OREF's available grants, after logging in, click the "Grant Opportunities" tab, then type "OREF" into the search box, or use the "Filter by Grant Maker" option at top left and select "Orthopaedic Research and Education Foundation" from the list.
Eligibility
OREF requires anorthopaedic surgeon in the role of Principal Investigator (PI) or co-PI who may be collaborating with a PhD and/or MD in order to foster the application of a full range of expertise, approaches, technologies, and creativity. A PhD may serve as the PI if an orthopaedic surgeon serves as co-PI with equal contributions. A PhD serving as PI or co-PI must hold a faculty appointment in an orthopaedic department. An MD serving as PI or co-PI must have a valid license to practice in the United States and must be either candidate, associate or full member in good standing of the Musculoskeletal Tumor Society (MSTS) in the United States.
View the RFA on proposalCentral for complete eligibility requirements.